{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:24:26Z","timestamp":1791919466982,"version":"4.3.4"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,9,28]],"date-time":"2016-09-28T00:00:00Z","timestamp":1475020800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100008247","name":"University of Otago","doi-asserted-by":"publisher","award":["not given"],"award-info":[{"award-number":["not given"]}],"id":[{"id":"10.13039\/100008247","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Ross Bailey Nephrology Trust","award":["not given"],"award-info":[{"award-number":["not given"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1007\/s00228-016-2133-y","type":"journal-article","created":{"date-parts":[[2016,9,27]],"date-time":"2016-09-27T23:09:35Z","timestamp":1475017775000},"page":"71-78","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["A population pharmacokinetic model to predict oxypurinol exposure in patients on haemodialysis"],"prefix":"10.1007","volume":"73","author":[{"given":"Daniel FB","family":"Wright","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew P.","family":"Doogue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murray L","family":"Barclay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter T","family":"Chapman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas B","family":"Cross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John H","family":"Irvine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa K","family":"Stamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,9,28]]},"reference":[{"issue":"7","key":"2133_CR1","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.3899\/jrheum.110273","volume":"38","author":"LK Stamp","year":"2011","unstructured":"Stamp LK, Khanna PP, Dalbeth N, Boers M, Maksymowych WP, Schumacher HR Jr, Becker MA, MacDonald PA, Edwards NL, Singh JA, Simon LS, McQueen FM, Neogi T, Gaffo AL, Strand V, Taylor WJ (2011) Serum urate in chronic gout\u2014will it be the first validated soluble biomarker in rheumatology? J Rheumatol 38(7):1462\u20131466","journal-title":"J Rheumatol"},{"key":"2133_CR2","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1002\/acr.21772","volume":"64","author":"D Khanna","year":"2012","unstructured":"Khanna D, Khanna PP, Foitzgerald JD et al (2012) American College of Rheumatology Guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res 64:1431\u20131446","journal-title":"Arthritis Care Res"},{"issue":"8","key":"2133_CR3","doi-asserted-by":"crossref","first-page":"623","DOI":"10.2165\/00003088-200746080-00001","volume":"46","author":"RO Day","year":"2007","unstructured":"Day RO, Graham GG, Hicks M, McLaclan AJ, Stocker SL, Williams KM (2007) Clinical pharmacokinetics and pharmacodynamics of allopurinol and oxypurinol. Clin Pharmacokinet 46(8):623\u2013644","journal-title":"Clin Pharmacokinet"},{"key":"2133_CR4","unstructured":"FDA US National Library of Medicine DailyMed: FDA information: allopurinol tablet (Zyloprim) (2012) http:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?id=13564 . Accessed 15 August 2016"},{"issue":"8","key":"2133_CR5","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1093\/rheumatology\/kem056a","volume":"46","author":"KM Jordan","year":"2007","unstructured":"Jordan KM, Cameron JS, Snaith M, Zhang W, Doherty M, Seckl J, Hingorani A, Jaques R, Nuki Gon behalf of the British Society for Rheumatology and British Health Professionals in Rheumatology Standards, Guidelines and Audit Working Group (SGAWG) (2007) British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of gout. Rheumatology 46(8):1372\u20131374","journal-title":"Rheumatology"},{"key":"2133_CR6","first-page":"29","volume-title":"The renal drug handbook, 3rd edn","author":"Anon","year":"2009","unstructured":"Anon (2009) Allopurinol. In: Ashley C, Currie A (eds) The renal drug handbook, 3rd edn. Radcliffe Publishing, Oxford, p. 29"},{"issue":"2","key":"2133_CR7","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1111\/bcp.12799","volume":"81","author":"DFB Wright","year":"2016","unstructured":"Wright DFB, Duffull SB, Merriman TR, Dalbeth N, Barclay ML, Stamp LK (2016) Predicting allopurinol response in patients with gout. Br J Clin Pharmacol 81(2):277\u2013289","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"2133_CR8","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/clpt.2011.113","volume":"90","author":"LK Stamp","year":"2011","unstructured":"Stamp LK, Barclay ML, O'Donnell JL, Zhang M, Drake J, Frampton C, Chapman PT (2011) Relationship between serum urate and plasma oxypurinol in the management of gout: determination of minimum plasma oxypurinol concentration to achieve a target serum urate level. Clin Pharmacol Ther 90(3):392\u2013398","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"2133_CR9","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1111\/j.1365-2125.2012.04207.x","volume":"74","author":"SL Stocker","year":"2012","unstructured":"Stocker SL, McLachlan AJ, Savic RM, Kirkpatrick CM, Graham GG, Williams KM, Day RO (2012) The pharmacokinetics of oxypurinol in people with gout. Br J Clin Pharmacol 74(3):477\u2013489","journal-title":"Br J Clin Pharmacol"},{"issue":"7","key":"2133_CR10","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1007\/s00228-013-1478-8","volume":"69","author":"DF Wright","year":"2013","unstructured":"Wright DF, Stamp LK, Merriman TR, Barclay ML, Duffull SB, Holford NH (2013) The population pharmacokinetics of allopurinol and oxypurinol in patients with gout. Eur J Clin Pharmacol 69(7):1411\u20131421","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"2133_CR11","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000180580","volume":"16","author":"DW Cockcroft","year":"1976","unstructured":"Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16(1):31\u201341","journal-title":"Nephron"},{"key":"2133_CR12","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/j.1365-2125.2004.02114.x","volume":"58","author":"I Matthews","year":"2004","unstructured":"Matthews I, Kirkpatrick C, Holford N (2004) Quantitative justification for target concentration intervention\u2014parameter variability and predictive performance using population pharmacokinetic models for aminoglycosides. Br J Clin Pharmacol 58:8\u201319","journal-title":"Br J Clin Pharmacol"},{"key":"2133_CR13","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.2165\/00003088-200544100-00004","volume":"44","author":"S Janmahasatian","year":"2005","unstructured":"Janmahasatian S, Duffull SB, Ash S, Ward LC, Byrne NM, Green B (2005) Quantification of lean bodyweight. Clin Pharmacokinet 44:1051\u20131065","journal-title":"Clin Pharmacokinet"},{"key":"2133_CR14","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1146\/annurev.pharmtox.48.113006.094708","volume":"48","author":"BJ Anderson","year":"2008","unstructured":"Anderson BJ, Holford NHG (2008) Mechanism-based concepts of size and maturity in pharmacokinetics. Ann Rev Pharmacol Toxicol 48:303\u2013332","journal-title":"Ann Rev Pharmacol Toxicol"},{"key":"2133_CR15","first-page":"387","volume":"12","author":"AS Michaels","year":"1966","unstructured":"Michaels AS (1966) Operating parameters and performance critieria for hemodialyzers and other membrane-separation devices. Trans Am Soc Artif Intern Organs 12:387\u2013392","journal-title":"Trans Am Soc Artif Intern Organs"},{"issue":"4","key":"2133_CR16","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s40262-014-0203-9","volume":"54","author":"N Plock","year":"2015","unstructured":"Plock N, Facius A, Lahu G, Wood N, Frigo T, Deveney A, Aceves P (2015) Population pharmacokinetic meta-analysis to bridge ferumoxytol plasma pharmacokinetics across populations. Clin Pharmacokinet 54(4):385\u2013395","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"2133_CR17","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/0002-9343(84)90743-5","volume":"76","author":"KR Hande","year":"1984","unstructured":"Hande KR, Noone RM, Stone WJ (1984) Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency. Am J Med 76(1):47\u201356","journal-title":"Am J Med"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-016-2133-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00228-016-2133-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-016-2133-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,24]],"date-time":"2017-06-24T19:50:26Z","timestamp":1498333826000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00228-016-2133-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9,28]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["2133"],"URL":"https:\/\/doi.org\/10.1007\/s00228-016-2133-y","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,9,28]]}}}